SEC Form 4 · accession 0000899243-19-005958
Kaleido Biosciences, Inc. · KLDO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joshua T Brumm
Officer — See Remarks
Period of report
Mar 4, 2019
Accepted (ET)
Mar 4, 2019 · 8:10 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001751299
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $15.00 | Mar 4, 2019 | A | 80,000 | A | — | Mar 4, 2029 | Common Stock | 80,000 | 80,000 | D |
Explanation of responses
- F125% of this option shall vest on January 23, 2020, with the remainder vesting in 12 equal quarterly installments thereafter.
Remarks
Title: Chief Operating Officer and Chief Financial Officer